Change in Foveal Avascular Zone After Removal of Epiretinal Membrane and Internal Limiting Membrane
Launched by SAMSUNG MEDICAL CENTER · Nov 10, 2013
Trial Information
Current as of April 26, 2025
Unknown status
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • epiretinal membrane
- Exclusion Criteria:
- • history of vitrectomy, intraocular surgery
- • any macular disease other than epiretinal membrane
- • media opacity obscuring the image of fluorescein angiography
About Samsung Medical Center
Samsung Medical Center (SMC) is a leading healthcare institution in South Korea, renowned for its commitment to advancing medical research and innovation. As a prominent clinical trial sponsor, SMC integrates cutting-edge technology and expert clinical practices to conduct rigorous studies aimed at improving patient outcomes. The center is dedicated to fostering collaborations with global research entities and adhering to the highest ethical standards, ensuring the integrity and reliability of its clinical trials. With a focus on diverse therapeutic areas, SMC plays a pivotal role in translating scientific discoveries into effective treatments, ultimately enhancing the quality of healthcare worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Seoul, , Korea, Republic Of
Patients applied
Trial Officials
Se Woong Kang, MD
Principal Investigator
Samsung Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials